MyoKardia Lands $46,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    333 Allerton Ave. South San Francisco, CA 94080 USA
  • Company Description
    MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company’s first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to advance and expand the company’s portfolio of potential therapies for hypertrophic and dilated cardiomyopathies (HCM and DCM), including its lead drug candidate, MYK-461, which is currently in Phase 1 clinical trials.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy